Observational Study to Investigate the Effectiveness and Safety of Olostar Tab in Patients With Essential Hypertension and Dyslipidemia

Daewoong Pharmaceutical Co. LTD.9,707 enrolled

Overview

The purpose of this study is to investigate the effectiveness and safety of Olostar Tab in patients with essential hypertension and dyslipidemia

Study Type

OBSERVATIONAL

Enrollment

9,707

Conditions

Hypertension Dyslipidemias

Interventions

Other: Not applicable-observational studyDRUG

Eligibility

Sex: ALLMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female ≥ 19 * Patients have record of blood pressure (SBP/DBP) and LDL-C after prescription of Olostar Tab. Exclusion Criteria: * Patients that have participated clinical trials or PMS with Olostar Tab.

Locations (1)

Dongguk Ilsan University Hospital

Ilsan, South Korea

RECRUITING

Outcomes

Primary Outcomes

Percent change from baseline in blood pressure (SBP/DBP)

Time frame: At 8 Weeks

Percent change from baseline in LDL-Cholesterol (LDL-C)

Time frame: At 8 Weeks

Central Contacts

Daewoong Clinical

CONTACT

+82-2-550-8800

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.